Drug intelligence / Profile preview

Qing Bai Chi Dan Decoction

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Qing Bai Chi Dan Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by Guang'anmen Hospital, China Academy of Chinese Medical Sciences. It is investigated for the maintenance treatment of systemic lupus erythematosus (SLE), specifically for patients presenting with the Yin-deficiency and internal heat pattern according to TCM principles. The decoction is typically administered as granules in combination with standard-of-care therapies, such as glucocorticoids (e.g., prednisone) and antimalarials (e.g., hydroxychloroquine). Its primary therapeutic goal is to maintain disease stability and facilitate the tapering of glucocorticoid doses while managing SLE disease activity over a 24-week treatment period.

Other names: Qing Bai Chi Dan granules

Beyond the preview

Go deeper on Qing Bai Chi Dan Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qing Bai Chi Dan Decoction.

Explore the full profile